Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00339651 · ClinicalTrials.gov registry record

Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
745
Enrollment target

NCT00339651: Completed study, sponsored by National Cancer Institute (NCI).

NCT00339651 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 745 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00339651 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
745 participants
Enrollment target

Study Summary

This study, conducted jointly by the National Cancer Institute and the Kaiser Permanente Center for Health Research Northwest (KPCHRN) in Portland, Oregon, will lay the groundwork for a future study to identify precursors of endometrial cancer; that is, conditions that precede development of cancer of the lining of the uterus. The diagnosis of endometrial hyperplasia (a condition of abnormal proliferation of endometrial tissue) includes most precursors of endometrial cancer, as well as many benign conditions. Currently, three methods of classifying endometrial cancer precursors have been suggested based on endometrial hyperplasia findings, but it is not known which classification best predicts cancer risk. This study will examine surgical specimens of hyperplasia and cancer from women diagnosed with endometrial cancer at least 2 years after a diagnosis of endometrial hyperplasia. Investigators will estimate the percentage of cases with different degrees of hyperplasia, and assess the subsequent cancers that developed. This will allow them to rank hyperplasia lesions according to cancer risk and identify lesions that represent the most immediate cancer precursors. They will also review patients medical charts for information related to cancer risk and treatment. Study participants will include women enrolled in the KPCHRN who are 40 years of age or older and who were diagnosed with endometrial cancer at least 2 years after being diagnosed with endometrial hyperplasia.

Trial Details

FieldValue
Enrollment Target 745 participants
Start Date 2002-11-25
Est. Completion 2020-08-06

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00339651

The ClinicalTrials.gov registry entry for NCT00339651 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 745 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00339651 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00339651 about?

NCT00339651 is a clinical study titled "Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer". This study, conducted jointly by the National Cancer Institute and the Kaiser Permanente Center for Health Research Northwest (KPCHRN) in Portland, Oregon, will lay the groundwork for a future study to identify precursors of endometrial cancer; that is, conditions that precede development of cancer ...

What is the current status of trial NCT00339651?

This trial is currently completed. The enrollment target is 745 participants. The study started on 2002-11-25. Estimated completion is 2020-08-06.

Who is sponsoring clinical trial NCT00339651?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.